Inactivating mutations of STAG2 cause cohesin defects and aneuploidy in some kinds of cancer cells [14], but not all tumor-derived STAG2 mutations confer defects in aneuploidy, indicating that loss of STAG2 may contribute to the pathogenesis or progression or therapy of human cancers by other unknown mechanisms. This evidence concerns the gene STAG2 and neoplasm.